IASO BIO’s Cell Therapy Summit Forum Successfully Held in Nanjing
2020 Nanjing International Life & Health Conference was successfully held in Nanjing International Expo Center during December 9 to 11. The conference was guided by Nanjing Municipal Government and hosted by Nanjing Jiangbei New Area. As one of the most significant sub-forum of the conference, the "Cell Therapy Summit Forum" organized by IASO BIO was successfully held on December 10. The forum has attracted a number of experts, scholars, industry pioneers and on-site audiences to attend and proved participants a lively exchange of forward looking ideas and the sharing of "opportunities & challenges faced by tumor immunotherapy".
Chen Chanmei, member of the Party Working Committee and Vice Director of the Management Committee of Nanjing Jiangbei New Area, made opening speech. “New medicine and lifescience industry is the landmark industry in Jiangbei new area of Nanjing. In recent years, it has shown a good development trend of increased industrial concentration and business agents, sufficient innovation resources and great potential in technology transformation. As a star enterprise in the biopharmaceutical valley of Jiangbei new area, IASO BIO has witnessed it's achievements in the industry since its establishment. We welcome more promising companies to join the new area to jointly promote the development of human life and health. In the future, the new area will also build more industrial public service platforms, create better conditions for innovative talents and innovative capital, promote the integration of basic research and industrial integration, and create a source of innovation in the field of life and health.”
Opening speech by Chen Chanmei, member of the Party Working Committee
and Vice Director of the Management Committeeof Nanjing Jiangbei New Area
The key message of this forum is to jointly promote basic medical and clinical research in the field of cell therapy, accelerate the research and development of innovative drugs for gene cell therapy and industrialization. Professor Zhou Jianfeng, Director of Department of Hematology, Tongji Hospital, Huazhong University of science & technology; Tong Chunrong, Vice President and Director of the first department of Hematology, Beijing Boren Hospital; Professor Liu Mingyao, director of Institute of Life Medicine, East China Normal University; Dr. Zheng Biao, Chief Scientific Officer of IASO BIO; Dr. Zhang Yu, Chief Scientific Officer and Senior Vice President of VCANBIO; Dr. Wang Yanbin, Chief Operating Officer of BioHeng Life Sciences, delivered keynote speeches on "opportunities and challenges faced by tumor immunotherapy", "car-t cell therapy", " combinational immunotherapy for cancer”, " gene editing and cell therapy", " new cell drug development and industrial transformation" and "universal Car-T", respectively, and interacted with the onsite audiences.
(From left to right: Professor Zhou Jianfeng, Director of Hematology, Tongji Hospital, Huazhong University of Science & Technology; Tong Chunrong, Vice President and Director of the Unit 1 of Department of Hematology, Beijing Boren Hospital; Professor Liu Mingyao, Director of the Institute of life medicine, East China Normal University; Dr. Zheng Biao, Chief Scientific Officer of IASO BIO; Dr. Zhang Yu, Chief Scientific Officer and Senior Vice President of VCANBIO; Dr. Wang Yanbin, Chief Operating Officer of BioHeng Life Sciences.)
Following the keynote speech, a panel discussion themed "From Bench to Bedside" was held with the host of Dr. Wang Wen, Chief Medical Officer of IASO BIO. All the experts had a heated discussion on "clinical needs and early research and development in cell therapy" from different perspectives. To meet clinical needs is always the ultimate purpose for new drug development. Although there are different needs between enterprises, doctors and scientists, these three parties are actually closely connected and should collaborate in the entire period. Experts believe that not only should we pay attention to the novelty and originality of the material basis, we should pay more attention to the clinical value. The basic R&D team must collaborate with first-line clinicians to carry out early R&D based more on clinical needs, and better deliver R&D results to the clinic side to make more patients truly benefit.
Pannel Discussion Session：From bench to Bedside
About 2020 Nanjing International Life & Health Conference
Themed on "Healthy Future", the 2020 Nanjing International Life & Health Conference was held in both modes of "offline and online live broadcast", including one main forum and more than 20 sub forums. The conference has invited a lot of well-known academicians, industry experts and leading enterprises at home and abroad to discuss on the innovative themes relating to small molecule innovative drugs, cell therapy, immunotherapy, antibody drugs, innovative medical devices, public health and preventive medicine, etc. The topics focus on the national strategic needs and industrial status. What’s more, the conference also set up high-quality exhibitions which areas covered biomedicine and services, precision medicine, innovative medical devices, epidemic prevention and control, attracting lots of exhibitors from leading enterprises at home and abroad.
